FDA's Guide: Recalling That Sketchy Lipstick Fast
Published Date: 12/18/2025
Notice
Summary
The FDA just dropped a draft guide to help cosmetic companies understand how mandatory recalls work and what to expect if their products need to be pulled from shelves. This guide answers common questions about the recall process, making it easier for businesses to stay safe and compliant. Companies should send their feedback by February 17, 2026, so the FDA can finalize the rules—keeping everyone on track and avoiding costly surprises.
Analyzed Economic Effects
5 provisions identified: 5 benefits, 0 costs, 0 mixed.
Draft Q&A on Mandatory Cosmetics Recalls
The FDA released a draft guidance titled "Questions and Answers Regarding Mandatory Cosmetics Recalls" that explains its current thinking on how mandatory cosmetics recalls will work, including the criteria, process, and expectations under section 611 of the FD&C Act (added by section 3502 of MoCRA). The document is presented as questions and answers to help regulated cosmetic industry members understand recall implementation.
Guidance Is Nonbinding; Alternatives Allowed
The draft guidance says it does not establish any rights and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations.
No New Information-Collection Burden
FDA tentatively concluded that the draft guidance contains no collection of information, so Office of Management and Budget clearance under the Paperwork Reduction Act of 1995 is not required. This means the draft guidance does not add new paperwork requirements as written.
Deadline to Comment on Draft Guidance
If you want FDA to consider your feedback before it begins work on the final guidance, submit electronic or written comments by February 17, 2026. Comments submitted to https://www.regulations.gov will be posted publicly unless submitted as confidential written/paper submissions following FDA instructions.
FDA Will Consider Comments on Costs
As FDA develops final guidance, the Agency will consider comments on costs or cost savings the guidance may generate, which is relevant to Executive Order 14192. Stakeholders can submit such cost-related comments for FDA to review when finalizing the guidance.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13716 — New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor
The FDA just updated the rules for new animal drugs, approving several new and generic medicines for pets and farm animals from early 2026. These changes help keep animal treatments safe and effective, and the updates take effect right away on July 7, 2026. If you’re a drug maker or animal caretaker, these approvals and sponsor changes could impact what medicines are available and when.
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
2026-13519 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Premarket Approval of Medical Devices
The FDA is asking for public feedback on their paperwork rules for approving the most important and risky medical devices, like life-support machines. This review helps keep devices safe and effective before they hit the market. If you have thoughts, you’ve got until August 5, 2026, to share them—no cost changes, just a check-in on the info they collect.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13533 — Agency Information Collection Activities; Proposed Collection; Comment Request; Biologics License Applications, Procedures and Requirements
The FDA wants your thoughts on how it collects info for biologics license applications—basically, the paperwork needed to approve new biological medicines. This affects companies making these medicines and anyone involved in the approval process. You’ve got until September 4, 2026, to share your comments, so don’t miss out on shaping the rules and possibly saving time and money!
Previous / Next Documents
Previous: 2025-23247 — Chromium Trioxide From India and Turkey; Revised Schedule for the Subject Proceeding
The U.S. International Trade Commission is updating the timeline for its investigation into chromium trioxide imports from India and Turkey. This affects companies involved in importing or producing this chemical, with the Commission’s final views now due by January 7, 2026. The change could impact trade decisions and any related duties or regulations soon.
Next: 2025-23251 — Submission for OMB Review; 30-Day Comment Request; Special Volunteer and Guest Researcher Assignment (Office of Intramural Research, Office of the Director)
The NIH is asking for a 30-day public comment on their request to keep collecting info from special volunteers and guest researchers. This affects people who work or volunteer in NIH research programs and won’t cost anyone extra money. They want to make sure their forms stay approved and easy to use, so the research keeps running smoothly.